![](/wp-content/uploads/2024/05/Screenshot-2024-05-06-at-4.44.51%E2%80%AFPM.png)
$599
Xeris Exclusively Partners with Beta Bionics; Eccogene IPO in 2025?
Two cardiometabolic-related news items have been observed: Xeris Biopharma partnered with Beta Bionics for the exclusive development and commercialization of a glucagon product (view press release); and Eccogene is reportedly considering an IPO early 2025 as it advances its MASH pipeline (view article). Below, FENIX provides highlights and insights for the respective news items.